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SECTION I: USE OF THE CLINICAL PRACTICE GUIDELINE
This Clinical Practice Guideline document is based upon the best information available as of
February 2011. It is designed to provide information and assist decision-making. It is not
intended to define a standard of care, and should not be construed as one, nor should it be
interpreted as prescribing an exclusive course of management. Variations in practice will
inevitably and appropriately occur when clinicians take into account the needs of individual
patients, available resources, and limitations unique to an institution or type of practice. Every
health-care professional making use of these recommendations is responsible for evaluating the
appropriateness of applying them in the setting of any particular clinical situation. The
recommendations for research contained within this document are general and do not imply a
specific protocol.
SECTION II: DISCLOSURE
Kidney Disease: Improving Global Outcomes (KDIGO) makes every effort to avoid any actual or
reasonably perceived conflicts of interest that may arise as a result of an outside relationship or a
personal, professional, or business interest of a member of the Work Group. All members of the
Work Group are required to complete, sign, and submit a disclosure and attestation form
showing all such relationships that might be perceived or actual conflicts of interest. This
document is updated annually and information is adjusted accordingly. All reported information
is published in its entirety at the end of this document in the Work Group members’
Biographical and Disclosure Information section, and is kept on file at the National Kidney
Foundation (NKF), Managing Agent for KDIGO.
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